AnnMarie Liapakis

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

David Roth, David R. Nelson, Annette Bruchfeld et al. · The Lancet · 2015 · 666 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation

Josh Levitsky, Richard N. Formica, Roy D. Bloom et al. · American Journal of Transplantation · 2017 · 321 citations · Full text

Medicine, Infectious Diseases, Surgery +16

Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function

Varun Saxena, Farrukh M. Koraishy, Meghan E. Sise et al. · Liver International · 2016 · 298 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade

Albert Do, Yash Mittal, AnnMarie Liapakis et al. · PLoS ONE · 2015 · 65 citations · Full text

Pharmacy, Pharmacotherapy, Drug Approval Processes +15

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target

Varun Saxena, Farrukh M. Koraishy, Meghan E. Sise et al. · Journal of Hepatology · 2015 · 40 citations

Pharmacy, Infectious Diseases, Nephrology +15